Rituxan (Rituximab) (Genentech Inc. and Biogen Idec Inc.) for systemic lupus erythematosus

Record ID 32011000843
English
Authors' objectives:

Systemic lupus erythematosus (SLE) is a chronic, inflammatory autoimmune disorder. It is characterized by the involvement of multiple organ systems, a clinical pattern of flares and remissions, and the presence of autoantibodies. Prevalence estimates vary widely, due, at least in part, to difficulties with accurate diagnosis. The incidence of SLE is influenced by sex and race. The cause of SLE is not known, and there is no cure for SLE. Treatment is aimed at controlling symptoms. Some patients with SLE develop deposits of antibodies within the kidneys, which can lead to a condition called lupus nephritis (LN) and kidney failure in severe cases. Refractory manifestations and treatment-related complications of SLE remain major causes of mortality and morbidity.

Details
Project Status: Completed
URL for project: http://www.hayesinc.com
Year Published: 2010
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: United States
MeSH Terms
  • Lupus Erythematosus, Systemic
Contact
Organisation Name: HAYES, Inc.
Contact Address: 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name: saleinfo@hayesinc.com
Contact Email: saleinfo@hayesinc.com
Copyright: 2010 Winifred S. Hayes, Inc
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.